Standards for Clinical Trials in Sexual Dysfunction in Women: Research Designs and Outcomes Assessment

被引:35
作者
Clayton, Anita H. [1 ]
Dennerstein, Lorraine [2 ]
Fisher, William A. [3 ]
Kingsberg, Sheryl A. [4 ]
Perelman, Michael A. [5 ]
Pyke, Robert E. [6 ]
机构
[1] Univ Virginia Hlth Syst, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22903 USA
[2] Univ Melbourne, Off Gender & Hlth, Natl Aging Res Inst, Melbourne, Vic, Australia
[3] Univ Western Ontario, London, ON, Canada
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[6] Boehringer Ingelheim Pharmaceut Inc, Clin Res, Ridgefield, CT USA
关键词
Female Sexual Dysfunction; FSD; Clinical Trials; Research Design; TRANSDERMAL TESTOSTERONE TREATMENT; DISTRESS SCALE FSDS; FUNCTION INDEX FSFI; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; AROUSAL DISORDER; DESIRE DISORDER; ERECTILE DYSFUNCTION; PREMENOPAUSAL WOMEN; SILDENAFIL CITRATE;
D O I
10.1111/j.1743-6109.2009.01628.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Clinical trial design in female sexual dysfunction (FSD) is an evolving science, with some areas of controversy. Aim. To develop an evidence-based, expert consensus-report on design of FSD clinical research. Methods. Literature review including the Food and Drug Administration (FDA) clinical trial guidelines with critique by six experts from three countries, modified after public presentation and debate. Main Outcome Measure. Expert opinion and recommendations were based on grading of evidence based literature, internal committee dialogue, open presentation, and debate. Results. Design of clinical research for regulatory approval is driven by FDA guidelines. Diagnostic and Statistical Manual-IV definitions and consideration of comorbidity of sexual disorders may complicate patient selection and outcomes. Measures for study end points include satisfying sexual events utilizing a daily diary, sexual distress, and patient-reported outcomes measures of the construct under study. Currently, trial duration is recommended to be 6 months for efficacy trials to allow for modification of behavioral adaptations to changes in desire. Important issues include safety assessments, generalizability, having a representative study population, stratification by reproductive status, partner assessment, contextual and interpersonal factors, symptom duration and severity, management of placebo response, and drug dosing. Statistical analysis should include assessment of change from baseline to end point between study drug and placebo, determination of statistically significant change vs. clinically meaningful effects, linear mapping of all measures of the same construct, and determination of responders and remitters. Conclusions. Future trials should include clear population definitions, direct and indirect measures of the specific FSD construct, and procedures to allow generalizability of diagnosis and treatment to the target population. Clayton AH, Dennerstein LD, Fisher WA, Kingsberg SA, Perelman MA, and Pyke RE. Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J Sex Med 2010;7:541-560.
引用
收藏
页码:541 / 560
页数:20
相关论文
共 61 条
[1]   Current perspectives on the clinical assessment and diagnosis of female sexual dysfunction and clinical studies of potential therapies: A statement of concern [J].
Althof, SE ;
Dean, J ;
Derogatis, LR ;
Rosen, RC ;
Sisson, M .
JOURNAL OF SEXUAL MEDICINE, 2005, 2 :146-153
[2]  
[Anonymous], 2006, EUROPEAN PUBLIC ASSE
[3]  
[Anonymous], TXB ERECTILE DYSFUNC
[4]   Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder [J].
Basson, R ;
McInnes, R ;
Smith, MD ;
Hodgson, G ;
Koppiker, N .
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2002, 11 (04) :367-377
[5]   Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study [J].
Berman, JR ;
Berman, LA ;
Toler, SM ;
Gill, J ;
Haughie, S .
JOURNAL OF UROLOGY, 2003, 170 (06) :2333-2338
[6]  
Campbell Donald T., 1988, SELECTED PAPERS
[7]  
Caruso S, 2001, BRIT J OBSTET GYNAEC, V108, P623
[8]   Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study [J].
Caruso, Salvatove ;
Rugolo, Salvatore ;
Agnello, Carmela ;
Intelisano, Giorgia ;
Di Mari, Lucia ;
Cianci, Antonio .
FERTILITY AND STERILITY, 2006, 85 (05) :1496-1501
[9]   The assessment of sexual functions in women with male partners complaining of erectile dysfunction:: Does treatment of male sexual dysfunction improve female partner's sexual functions? [J].
Çayan, S ;
Bozlu, M ;
Canpolat, B ;
Akbay, E .
JOURNAL OF SEX & MARITAL THERAPY, 2004, 30 (05) :333-341
[10]   Prevalence of sexual dysfunction among newer antidepressants [J].
Clayton, AH ;
Pradko, JF ;
Croft, HA ;
Montano, CB ;
Leadbetter, RA ;
Bolden-Watson, C ;
Bass, KI ;
Donahue, RMJ ;
Jamerson, BD ;
Metz, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :357-366